Evidence map›Paper›PMID 33450210›Full record

ArticleMolecular cell2021

Mitochondrial NAD

Ann-Katrin Hopp, Federico Teloni, Lavinia Bisceglie, Corentin Gondrand, Fabio Raith, Kathrin Nowak, Lukas Muskalla, Anna Howald, Patrick G A Pedrioli, Kai Johnsson and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
4.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 59 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Hepatocyte mitochondrial NADNature metabolism · 2025
    Article
  7. Mitochondrial NADScience advances · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Subcellular NADNature metabolism · 2024
    Article
  19. Article
  20. Poly-ADP-ribosylation dynamics, signaling, and analysis.Environmental and molecular mutagenesis · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Ann-Katrin HoppDepartment of Molecular Mechanisms of Disease (DMMD), University of Zurich, 8057 Zurich, Switzerland; Life Science Zurich Graduate School, Molecular Life Science Ph.D. Program, University of Zurich, 8057 Zurich, Switzerland.
Federico TeloniDepartment of Molecular Mechanisms of Disease (DMMD), University of Zurich, 8057 Zurich, Switzerland; Life Science Zurich Graduate School, Molecular Life Science Ph.D. Program, University of Zurich, 8057 Zurich, Switzerland.
Lavinia BisceglieDepartment of Molecular Mechanisms of Disease (DMMD), University of Zurich, 8057 Zurich, Switzerland; Life Science Zurich Graduate School, Molecular Life Science Ph.D. Program, University of Zurich, 8057 Zurich, Switzerland.
Corentin GondrandDepartment of Chemical Biology, Max Planck Institute for Medical Research, 69120 Heidelberg, Germany.
Fabio RaithDepartment of Chemical Biology, Max Planck Institute for Medical Research, 69120 Heidelberg, Germany; Faculty of Chemistry and Earth Sciences, University of Heidelberg, 69120 Heidelberg, Germany.
Kathrin NowakDepartment of Molecular Mechanisms of Disease (DMMD), University of Zurich, 8057 Zurich, Switzerland; Life Science Zurich Graduate School, Molecular Life Science Ph.D. Program, University of Zurich, 8057 Zurich, Switzerland.
Lukas MuskallaDepartment of Molecular Mechanisms of Disease (DMMD), University of Zurich, 8057 Zurich, Switzerland; Life Science Zurich Graduate School, Cancer Biology Ph.D. Program, University of Zurich, 8057 Zurich.
Anna HowaldDepartment of Molecular Mechanisms of Disease (DMMD), University of Zurich, 8057 Zurich, Switzerland.
Patrick G A PedrioliDepartment of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland; PHRT-CPAC, ETH Zurich, 8093 Zurich, Switzerland.
Kai JohnssonDepartment of Chemical Biology, Max Planck Institute for Medical Research, 69120 Heidelberg, Germany.
Matthias AltmeyerDepartment of Molecular Mechanisms of Disease (DMMD), University of Zurich, 8057 Zurich, Switzerland.
Deena M Leslie PedrioliDepartment of Molecular Mechanisms of Disease (DMMD), University of Zurich, 8057 Zurich, Switzerland.
Michael O HottigerDepartment of Molecular Mechanisms of Disease (DMMD), University of Zurich, 8057 Zurich, Switzerland. Electronic address: michael.hottiger@dmmd.uzh.ch.
University of Zurich · CHMax Planck Institute for Medical Research · DEETH Zurich · CHHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In addition to its role as an electron transporter, mitochondrial nicotinamide adenine dinucleotide (NAD

Indexed as

ADP-RibosylationAnimalsAntimycin ACell LineCell Line, TumorCell NucleusChromatinElectron TransportHeLa CellsHumansHydrogen PeroxideMethacrylatesMiceMice, Inbred C57BLMitochondriaMyoblastsantimycinAntimycin AChromatinHydrogen PeroxideMethacrylatesmyxothiazolNADOligomycinsPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1RotenoneThiazolesADP-ribosylationARTD1DNA damagemitochondriamitochondrial ADP-ribosylationmito-nuclear crosstalkNADPARP1PARP-inhibitorPARP inhibitors

Identifiers

PMID33450210
PMCPMC7837215
OpenAlexW3120852312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.